matrix m1
Vaccineexperimental
Clinical trial activity
61 trials · 41 clinical orgs · 0 marketing orgs
Phase 1
37
Phase 2
30
Phase 3
9
Phase 4
2
Earliest trial started Aug 1, 2008 (NCT00942071)
Timeline
Indications
Approved for
Studied for
- Adjuvants, Vaccine · Phase 1
- COVID-19 · Phase 3
- Diarrhea · Phase 3
- Epstein-Barr Virus Infections · Phase 1/Phase 2
- Fever · Phase 2/Phase 3
- Healthy Volunteers · Phase 2
- Hemorrhagic Fever, Ebola · Phase 1
- Herpesviridae · Phase 1/Phase 2
- Herpesvirus 4, Human · Phase 1
- Infections · Phase 1/Phase 2
- Infectious Mononucleosis · Phase 1/Phase 2
- Influenza, Human · Phase 2/Phase 3
- Irritable Mood · Phase 2/Phase 3
- Malaria · Phase 4
- Malaria, Falciparum · Phase 4
- Malaria, Vivax · Phase 1/Phase 2
- Nausea · Phase 2/Phase 3
- Parasitic Diseases · Phase 1/Phase 2
- Plasmodium falciparum · Early Phase 1
- Protozoan Infections · Phase 1
- Respiratory Syncytial Viruses · Phase 2
- Rotavirus Infections · Phase 3
- Severe Acute Respiratory Syndrome · Phase 3
- Vaccines · Phase 4
- Vector Borne Diseases · Phase 1/Phase 2
- Vomiting · Phase 2/Phase 3
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650407 ↗
Also known as
- matrix m
- matrix m1
- matrix-m1
- rotavin-m1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07194668 | Phase 4 | Dec 1, 2025 | University of Oxford |
| NCT07183371 | Phase 2 | Nov 30, 2025 | European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative (EVI), Heidelberg, Germany, Government of Germany, Institut et Haute école de la Santé, La Source, University of Oxford |
| NCT06958198 | Phase 1 | Sep 15, 2025 | European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative (EVI), Heidelberg, Germany, Government of Germany, Institut et Haute école de la Santé, La Source, University of Oxford, Wellcome Trust |
| NCT07147400 | Phase 2 | Aug 22, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), Serum Institute of India Pvt. Ltd. |
| NCT06816524 | N/A | Jul 1, 2025 | Jomo Kenyatta University of Agriculture and Technology, National Institute for Public Health and the Environment, RIVM, Holland, Radboud University, Swiss Federal Institute of Technology |
| NCT06080243 | Phase 2 | Feb 1, 2025 | European Vaccine Initiative (EVI), Heidelberg, Germany, Malaria Research and Training Center, Bamako, Mali, University of Oxford |
| NCT06482359 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2024 | Novavax |
| NCT06291857 | Phase 3 | Oct 21, 2024 | Novavax |
| NCT06320535 | Phase 1 | Mar 25, 2024 | Bill and Melinda Gates Foundation, University Hospitals Bristol NHS Foundation Trust, University of Oxford |
| NCT06068530 | Phase 4 | Nov 1, 2023 | Mahidol University, University of Oxford |
| NCT05683834 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05978037 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2023 | University of Oxford |
| NCT05913973 | Phase 1 | Aug 4, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06141057 | Phase 1 | Jun 6, 2023 | University of Oxford |
| NCT05790889 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2023 | European and Developing Countries Clinical Trials Partnership (EDCTP), Institut et Haute école de la Santé, La Source, University of Oxford, Wellcome Trust |
| NCT05875701 | Phase 3 | Mar 28, 2023 | Novavax |
| NCT05357560 | Phase 1 | Feb 28, 2023 | European and Developing Countries Clinical Trials Partnership (EDCTP), Medical Research Council, The Gambia, University of Oxford |
| NCT05519839 | Phase 2 | Jan 16, 2023 | Novavax |
| NCT05400746 | Early Phase 1 (Phase 1) | Nov 2, 2022 | University of Oxford |
| NCT05385471 | Early Phase 1 (Phase 1) | Nov 1, 2022 | Churchill Hospital, Oxford, University of Oxford |
Showing 20 of 61 trials
Page 1 / 4
Organizations
Research & Development (41)
41 organizations
Page 1 / 3